论文部分内容阅读
晚期非小细胞肺癌(NSCLC)的治疗需首先明确其组织学类型与分子学特征。若存在表皮生长因子受体(EGFR)基因突变或渐变性淋巴瘤激酶(ALK)基因融合,应首选分子靶向药物治疗。但分子靶向治疗药物并未改善晚期患者的总生存,如何提高晚期NSCLC患者的总生存是目前临床医生关注的热点。表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)与含铂双药交替使用模式作为晚期NSCLC的一线治疗方案,可能将明显延长EGFR阳性突变患者总生存时间。本文就小分子酪氨酸激酶抑制剂联合化疗治疗NSCLC患者、方式及其疗效的研究进展进行综述。
The treatment of advanced non-small cell lung cancer (NSCLC) needs to first clarify its histological type and molecular characteristics. Molecular targeted drug therapy should be the first choice if there is a mutation of the epidermal growth factor receptor (EGFR) or a fusion of a progressive lymphoma kinase (ALK) gene. However, molecular targeted therapy does not improve the overall survival of patients with advanced stage, how to improve the overall survival of patients with advanced NSCLC is currently the focus of attention of clinicians. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and platinum-containing double-drug alternating mode of use as a first-line treatment of advanced NSCLC may significantly extend the overall survival of patients with EGFR-positive mutations. This article reviews the research progress of small molecule tyrosine kinase inhibitors combined with chemotherapy in patients with NSCLC, their modalities and their therapeutic effects.